The SOT-Sponsored Meetings described in this Science Alert may be of interest to you. For additional information, please contact the organizers of these meetings directly.
SOT CCT on Use of Cardiomyocytes for the Assessment of Proarrhythmic Risk, October 25–26: Abstract Site Now Open
The Society of Toxicology Contemporary Concepts in Toxicology (SOT CCT) conference on The Use of Cardiomyocytes for the Assessment of Proarrhythmic Risk will be held October 25–26, 2016, in Arlington, Virginia. Human stem cell-derived cardiomyocytes (hiPSC-CMs) are increasingly used in drug discovery, toxicity assessment, and cell-based disease treatment. In vitro screening assays also are used to make decisions about which drug candidates to progress into development. In light of the potential utility of this emergent technology, this workshop will engage experts in presenting and discussing various aspects of the phenotype of these cells (functional, proteins, biochemical) and comparing them to adult ventricular CMs, as a basis for assessing their potential uses in drug and chemical safety testing. This workshop will include domestic and international scientists from government agencies, pharmaceutical industry, and academia to discuss the current state of the art and the path forward. For more information, to submit an abstract, and to register, please visit the conference website.
SOT CCT on Toxicoepigenetics: The Interface of Epigenetics and Risk Assessment, November 2–4
The SOT CCT conference on Toxicoepigenetics: The Interface of Epigenetics and Risk Assessment, will be held November 2–4, 2016, in Tysons, Virginia. The epigenome is a dynamic regulatory framework that controls the use of genomic information to govern the response of cells, tissues, organs, and individuals to their environment. As a master regulator of gene expression, the epigenome is responsive to a diverse range of environmental factors including toxicant exposure, diet, stress, and socioeconomic circumstances. Traditional toxicological paradigms have relied on factors such as age, genetic polymorphisms, and disease status to identify variability in responsiveness to environmental toxicant exposure; however, these factors are neither sufficient to faithfully identify differentially responsive individuals, nor are they modifiable factors that can be leveraged to mitigate adverse health effects of toxicant exposures. An individual’s epigenome, on the other hand, is malleable and shaped by interactions with chemical and non-chemical aspects of the environment, giving it potential as a tool for the promotion of public health. This conference will examine the state of the science to identify potential applications and predictable limitations facing the integration of epigenetic data into human health risk assessment paradigms. For more information, please visit the conference website.
SOT CCT on Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic, March 11, 2017
The SOT CCT conference on Metabolic Syndrome and Associated Diseases: From Bench to the Clinic will be held on Saturday, March 11, 2017, in Baltimore, Maryland, the day before the 56th SOT Annual Meeting. Metabolic syndrome is defined by a combination of risk factors that can lead to greater potential for type 2 diabetes, obesity, lipid disorders, cardiovascular disease, and other circulatory disorders. There is currently a significant research focus to understand the key pathways that control metabolism, as these pathways would be likely targets of risk factors such as environmental chemical exposures, microbiome, nutrition, and exercise. Moreover, it is likely that there are pathways that are of importance to controlling metabolism that would be targets of both environmental chemicals and pharmaceutical interventions. A multidisciplinary approach to understand the underlying biological mechanisms and translate that knowledge into prevention and treatment is required. This conference will focus on understanding the pathways and risk factors leading to disease and how these pathways can be perturbed to develop drugs for disease interventions. This meeting creates a unique combination that is likely to lead to new thought processes and scientific collaborations in addition to defining knowledge gaps, identifying research needs, protecting public health, and empowering product development. More information will be available in the weeks ahead.